Abram Scientific Raises $11.75M Series A to Advance Rapid Coagulation Diagnostics Platform CoagCare

New updates have been reported about Abram Scientific.

Abram Scientific has secured $11.75 million in Series A funding to accelerate development and regulatory progress of its CoagCare point-of-care coagulation diagnostic system. The round, led by Octapharma AG with participation from investors affiliated with the University of Colorado Anschutz, is intended to move CoagCare through key clinical milestones and toward U.S. FDA 510(k) clearance.

CoagCare is a portable, single-use card and meter platform designed to deliver full viscoelastic assessment of the coagulation cascade, from clot formation through fibrinolysis, in under 10 minutes from a drop of blood. Positioned as a faster alternative to existing technologies such as TEG and ROTEM, which often require 30–60 minutes, CoagCare targets critical-care, trauma, surgical, and pre-hospital settings where rapid, goal-directed transfusion and therapy decisions are financially and clinically material.

The new capital strengthens Abram Scientific’s ability to industrialize its technology, expand validation studies, and build the data required to influence clinical protocols in bleeding management and critical care. CEO and founder Dr. Abhishek Ramkumar highlighted that the partnership with Octapharma and the University of Colorado brings not only funding, but strategic and clinical expertise to help position CoagCare as a next-generation standard for coagulation decision support.

For Octapharma, this marks a first major move into diagnostics, aligning its plasma-derived therapy portfolio with a platform that could optimize use of its products across the continuum of care. Collaboration with CU Anschutz and its Center for COMBAT Research provides Abram Scientific with access to leading trauma and military-medicine researchers, supporting real-world testing in high-acuity environments. With 17 granted patents and additional applications pending, Abram Scientific is building an IP-backed, high-barrier position in rapid coagulation diagnostics as it works toward market entry and potential integration into global critical-care guidelines.